Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
levofloxacin
/
Generic mfg.
Welcome,
Profile
Billing
Logout
0 Diseases
137 Trials
137 Trials
5343 News
«
1
2
...
30
31
32
33
34
35
36
37
38
39
40
...
90
91
»
||||||||||
Targeted gene sequencing of H. pylori from FFPE gastric biopsies, to detect antimicrobial resistance
(C / 09) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_3492;
||||||||||
Establishment of MALDI-TOF database for Helicobacter pylori
(B / 07) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_3357;
||||||||||
Comparative study on the performance of single cell counting method for the detection of antimicrobial ssusceptibility of Gram-negative bacteria
(B / 01) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_3310;
||||||||||
Identifying confounding factors within a biofilm disruption assay using crystal violet
(B / 01) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_3302;
||||||||||
Impact of inoculum variation on the minimum inhibitory concentration of Mycobacterium tuberculosis using the reference EUCAST broth microdilution method against multiple antimycobacterial agents
(B / 05) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_3271;
||||||||||
levofloxacin
/
Generic mfg.
Multi-centre evaluation of Pseudomonas species with updated EUCAST v12.0 levofloxacin breakpoints for commercial dried Gram-negative MIC panels
(B / 03) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_3268;
||||||||||
Clinical manifestations, antimicrobial resistance and genomic feature analysis of the multidrug resistant Elizabethkingia strains
(B / 16) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_3246;
||||||||||
Emergence and clonal expansion of Aeromonas hydrophila ST1172, that simultaneously producing produces MOX-13 and OXA-724
(B / 16) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_3240;
||||||||||
tetracycline
/
Generic mfg.
Evaluation of short-term antimicrobial therapy with a combination of tetracyclines and fluoroquinolones for Japanese spotted fever
(B / 15) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_3211;
||||||||||
Human infections caused by Streptococcus canis : case series
(B / 11) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_3156;
||||||||||
Outcomes and predictors of clinical failure in Stenotrophomonas maltophilia infections in a tertiary care center: a retrospective observational study
(A / 09) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2971;
||||||||||
Bloodstream infections in Europe and United States: aetiology and antimicrobial susceptibility results from the SENTRY antimicrobial surveillance programmme (2019
(A / 09) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2961;
||||||||||
Potential concordance between surveillance culture isolates and organisms causing bacteraemia in haematological patients
(A / 09) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2959;
||||||||||
Molecular epidemiology of Klebsiella pneumoniae environmental isolates from a tertiary care hospital in Mexico
(C / 11) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2607;
||||||||||
Carbapenem-resistant Acinetobacter causing osteomyelitis and periprosthetic infections
(C / 05) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2471;
||||||||||
Using whole genome sequencing (WGS) to predict antimicrobial resistance (AMR) in the opportunistic pathogens Escherichia coli, Klebsiella pneumonia and Pseudomonas aeruginosa
(B / 11) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2346;
||||||||||
Genome-wide associations identify genetic markers for fluoroquinolone resistance levels in Escherichia coli from livestock animals
(B / 11) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2344;
||||||||||
Phenotypic and in silico characterization of carbapenem-resistant Serratia marcescens clinical isolates
(B / 13) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2304;
||||||||||
Quantifying the effects of antibiotic resistance gene presence on antibiotic susceptibility phenotypes in Escherichia coli
(B / 12) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2289;
||||||||||
Baxdela
(delafloxacin) /
Menarini, Melinta Therap
The importance of Glu-84 ParC in the resistance to delafloxacin in Staphylococcus aureus
(B / 07) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2276;
||||||||||
levofloxacin
/
Generic mfg.
,
clarithromycin
/
Generic mfg.
,
amoxicillin
/
Generic mfg.
In vitro bactericidal activity of amoxicillin combined to clarithromycin or levofloxacin on clinical strains of Helicobacter pylori
(B / 07) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2274;
||||||||||
In vitro efficacy of antibiotics used in clinical practice on clinical isolates of Helicobacter pylori
(B / 07) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2273;
||||||||||
Novel microfluidic system for antimicrobial susceptibility testing
(B / 02) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2165;
||||||||||
Emrok
(levonadifloxacin) /
Wockhardt
Clinical isolates of novel species of Stenotrophomonas sepilia are highly susceptible to novel benzoquinolizine quinolone agent levonadifloxacin
(B / 05) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2148;
||||||||||
Comparison of Ureaplasma Antibiotic Susceptibility Testing Using the Mycoplasma System Plus II and CLSI Methodology
(B / 05) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2141;
||||||||||
Toxigenic and non-toxigenic Vibrio cholerae can share the same MIC breakpoints
(B / 05) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2132;
||||||||||
Testing antibiotic tolerance of Staphylococcus aureus for clinical practice
(B / 05) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2127;
||||||||||
Characterisation of Acidaminococcus intestini infections
(B / 04) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2120;
||||||||||
Evaluation of EUCAST RAST from positive blood culture in comparison with Vitek 2 system in cancer patients from tertiary care hospital in resource limited settings
(B / 04) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2111;
||||||||||
aztreonam/avibactam
(PF-06947387) /
Pfizer, AbbVie
In vitro
(A / 16) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2096;
||||||||||
Virulence and resistance of Pseudomonas aeruginosa isolated from poultry
(A / 16) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2095;
||||||||||
Evolution of primary antimicrobial resistance among Helicobacter pylori in Belgium from 2013 to 2021
(A / 16) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2089;
||||||||||
Isolation of carbapenem-resistant Pseudomonas aeruginosa from Guanay Cormorants ( Phalacrocorax bougainvillii ) from Isla Pescadores, Lima, Peru
(A / 15) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2068;
||||||||||
Transferable quinolone resistance determinants in carbapenemase-producing Enterobacterales
(A / 14) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2050;
||||||||||
Spread of multidrug-resistant Pseudomonas aeruginosa ST3079 clone harbouring bla GES-1 and bla KPC-2 during the SARS-CoV-2 pandemic
(A / 14) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2049;
||||||||||
Zavicefta
(ceftazidime/avibactam) /
Pfizer, AbbVie
In vitro activity of ceftazidime-avibactam and comparator agents against MDR Pseudomonas aeruginosa , ATLAS Global Surveillance Program 2017-2021
(A / 13) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2037;
||||||||||
Antibiotic resistance profile of Helicobacter pylori cultivation from gastric biopsies
(A / 12) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2002;
||||||||||
Phenotypic and genotypic antibiotic susceptibility profiles of Pseudomonas aeruginosa from cystic fibrosis patients in South Africa
(A / 11) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_1990;
||||||||||
Zavicefta
(ceftazidime/avibactam) /
Pfizer, AbbVie
In vitro activity of ceftazidime/avibactam against Gram-negative bacteria collected from Croatia, Czech Republic, Hungary, Israel, Lithuania, Poland and Romania: ATLAS surveillance programme 2018, 2019, 2020
(A / 11) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_1989;
||||||||||
aztreonam/avibactam
(PF-06947387) /
Pfizer, AbbVie
In vitro activity of aztreonam-avibactam and comparator agents against clinical Enterobacterales isolates collected worldwide stratified by global region, ATLAS Global Surveillance Program, 2017-2021
(A / 08) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_1938;
||||||||||
Phenotypic and molecular characterisation of Vibrio cholerae non-O1/non-O139 strains from Germany and other European countries
(A / 07) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_1919;
||||||||||
Antimicrobial susceptibility of Gram-negative bacteria from China, the study for monitoring of antimicrobial resistance trends (SMART): from 2019 to 2020
(A / 07) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_1910;
||||||||||
Outbreak of Serratia marcesens co-producing NDM-1 plus OXA-48-like carbapenemases in an interzonal general hospital
(A / 07) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_1902;
||||||||||
Zerbaxa
(ceftolozane /tazobactam) /
Merck (MSD)
,
imipenem/relebactam
/
Merck (MSD)
Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical gram-negative pathogens before and during the COVID-19 pandemic: SMART United States 2018-2021
(A / 06) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_1898;
||||||||||
gepotidacin
(GSK2140944) /
GSK
In vitro activity of gepotidacin against Escherichia coli causing urinary tract infections between 2019-2021 in Europe, Russia, Israel, and Turkey, including molecularly characterized fluoroquinolone-resistant subsets
(A / 06) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_1889;
||||||||||
Drug resistance profiles of biofilm-producing isolates of Achromobacter , Burkholderia , and Stenotrophomonas species
(A / 06) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_1882;
||||||||||
Pseudomonas aeruginosa in pediatric patients with cystic fibrosis: clinical features, antibiotic susceptibility results, antibiotic resistance genes and molecular typing
(A / 06) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_1881;
||||||||||
Zerbaxa
(ceftolozane /tazobactam) /
Merck (MSD)
In vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa collected in the Study for Monitoring Antimicrobial Resistance Trends (SMART) between 2016-2019 in China
(A / 05) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_1877;
||||||||||
In vitro susceptibilities of Stenotrophomonas maltophilia isolates to antimicrobial agents commonly used for related infections: results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2004-2020
(A / 04) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_1851;
||||||||||
Zerbaxa
(ceftolozane /tazobactam) /
Merck (MSD)
Activity of ceftolozane/tazobactam and comparators against clinical Gram-negative pathogens and resistant phenotypes: SMART United States 2019-2021
(A / 04) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_1843;